Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Dr. Stephen Finn

Associate Professor Consultant (Histopathology)


Dr. Stephen Finn MB BAO BCh FDS PhD FRCPath FFPATH, is a Associate Professor, Consultant Pathologist and Principal Investigator at The University of Dublin, Trinity College and at St. James's Hospital Dublin, a tertiary referral cancer institution. He is co-director of the Cancer Molecular Diagnostic Laboratory, the only fully accredited molecular diagnostic laboratory in Ireland. His clinical practice is limited to Urological, Gastrointestinal and Liver pathology. Dr. Finn is former Senior Scientist and Staff Pathologist to the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute, Boston, USA. Dr. Finn continues to have strong personal and collaborative links to the Harvard School of Public Health, the Dana Farber Cancer Institute and the University of Orebro in Sweden. Dr. Finn is a member of the Irish Prostate Cancer Research Consortium (PCRC) and the Transdisciplinary Prostate Cancer Partnership ToPCaP. Dr. Finn, a current recipient of the Prostate Cancer Foundation Young investigator Award, and is committed to forging a career as an independent researcher focused on prostate cancer and bringing his skills as a clinician, pathologist and scientist to bear on critical questions of clinical relevance to men who suffer from aggressive prostate cancer.
 Identifying non-coding RNA repertoires of aggressive Prostate cancer
 EXPECT Trial: Evasion of immune editing by circulating tumour cells is an exercise-modifiable mechanism underlying aggressive behaviour in obese men with prostate cancer
 Discovery and Clinical Implementation of Novel Predictive Biomarkers for Enzalutamide therapy

Details Date
Chairman Molecular Pathology, Faculty of Pathology, RCPI 01/02/2011
Details Date From Date To
Fellow of the Royal College of Pathologists 2005 Current
Baird AM, Finn SP, Gray SG, Sheils O., Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16, (1), 2021, p14-16 , Journal Article, PUBLISHED  DOI
Bracken-Clarke D, Kapoor D, Baird AM, Buchanan PJ, Gately K, Cuffe S, Finn SP., Vaping and lung cancer - A review of current data and recommendations., Lung cancer (Amsterdam, Netherlands), 153, 2021, p11-20 , Journal Article, PUBLISHED  DOI
Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, Finn SP, Vander Heiden MG, Fiorentino M, Ebot EM, Mucci LA., Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021, Journal Article, PUBLISHED  DOI
Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, Kantarci AG, Finn SP., Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids., Journal of nanobiotechnology, 19, (71), 2021, p1-20 , Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
Hashim D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, Barber L, Pernar CH, Ebot EM, Isikbay M, Finn SP, Giovannucci EL, Lis RT, Loda M, Parmigiani G, Lotan T, Kantoff PW, Mucci LA, Graff RE., Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer., International journal of cancer, 146, (10), 2020, p2694-2702 , Journal Article, PUBLISHED  DOI
Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA; European Thoracic Oncology Platform Lungscape Consortium., Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort., Modern Pathology, 33, (5), 2020, p792 - 801, Journal Article, PUBLISHED
Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA., Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer., Clinical cancer research : an official journal of the American Association for Cancer Research, 26, (5), 2020, p1086-1093 , Journal Article, PUBLISHED  DOI
Malone T, Schäfer L, Simon N, Heavey S, Cuffe S, Finn S, Moore G, Gately K., Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer., Pharmacology and Therapeutics, 207, 2020, Journal Article, PUBLISHED  DOI
Silva R, Moran B, Russell NM, Fahey C, Vlajnic T, Manecksha RP, Finn SP, Brennan DJ, Gallagher WM, Perry AS., Evaluating liquid biopsies for methylomic profiling of prostate cancer., Epigenetics, 15, (6-7), 2020, p715-727 , Journal Article, PUBLISHED  DOI
Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M, Mucci LA., Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer., Carcinogenesis, 41, (7), 2020, p904-908 , Journal Article, PUBLISHED  DOI

Page 1 of 17